MediPal Holdings Corp - Company Profile
Powered by 
All the sales intelligence you need on MediPal Holdings Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how MediPal Holdings Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with MediPal Holdings Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MediPal Holdings Corp (MediPal) distributes pharmaceuticals, healthcare products, cosmetics, daily necessities, and animal health products. The company's product portfolio includes prescription pharmaceuticals, medical equipment, clinical diagnostic reagents, over-the-counter (OTC) pharmaceuticals, animal health products, daily necessities, cosmetics, food processing raw materials, and other essential products. The company caters its products and services to hospitals, clinics, dispensing pharmacies, drugstores, and various industries including healthcare, beauty, and food processing. The company operates a distribution network comprising area logistics centers (ALCs) and Medical Ryutsu Centers (MRCs). MediPal is headquartered in Chuo-ku, Tokyo, Japan.
Headquarters
Japan
Address
3-1-1, Kyobashi, Chuo-Ku, Tokyo, 104-8461
Website
www.medipal.co.jp
Telephone
81 3 35175800
No of Employees
13,061
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
7459 (TYO)
Revenue (2025)
$24.5B
4%
(2025 vs 2024)
EPS
XYZ
Net Income (2024)
XYZ
5.6%
(2024 vs 2023)
Market Cap*
$3.5B
Net Profit Margin (2025)
XYZ
0.9%
(2024 vs 2023)
* As of and is in US$
MediPal Holdings Corp premium industry data and analytics
Products and Services
| Products |
|---|
| Cosmetics |
| Clinical Diagnostic Reagents |
| Daily Necessities |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In October, the company's subsidiary MP Agro Co Ltd completed the acquisition of Cygni Holdings Inc. |
| 2025 | Contracts/Agreements | In September, the company entered into a licensing agreement with JCR Pharmaceuticals for JR-479, a therapy targeting GM2 gangliosidosis. |
| 2025 | Regulatory Approval | In September, the company was granted orphan drug designation to JR-446, an investigational drug for the treatment of mucopolysaccharidosis type IIIB by the Ministry of Health, Labour and Welfare of Japan. |
Competitor Comparison
| Key Parameters | MediPal Holdings Corp | Alfresa Holdings Corp | Otsuka Holdings Co Ltd | Suzuken Co Ltd | Ono Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chuo-Ku | Chiyoda-Ku | Minato | Nagoya | Osaka |
| State/Province | Tokyo | Tokyo | Tokyo | Aichi | Osaka |
| No. of Employees | 13,061 | 12,452 | 37,758 | 12,923 | 4,287 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Shuichi Watanabe | Chief Compliance Officer; Chief Executive Officer; Director; President | Executive Board | 2022 | 73 |
| Imagawa Kuniaki | Deputy Head-Pharmaceutical Business; Director | Executive Board | 2024 | 63 |
| Yasuhiro Choufuku | Vice President - Pharmaceutical Business; Director | Executive Board | 2025 | 71 |
| Yuji Sakon | General Manager - Administration Division; Managing Director | Executive Board | 2018 | 71 |
| Shinjiro Watanabe | System Manager; Director | Executive Board | 2025 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer